Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This pilot study gathered preliminary evidence of the safety and efficacy of four potencies
of smoked cannabis to manage chronic, treatment-resistant PTSD among veterans: (1) High THC/
Low CBD (High THC), (2) Low THC/High CBD (High CBD), (3) High THC/ High CBD (THC/CBD) and (4)
Low THC/Low CBD (placebo). The study will produce preliminary evidence to help elucidate the
potential effects of THC, CBD, or a combination of both constituents to reduce PTSD symptoms.
Smoked cannabis will be tested in two stages of three weeks each (Stage 1 and Stage 2), with
a two-week cessation period after each stage, verified by blood/urine cannabinoid analysis.
The primary objective was to compare three active concentrations of smoked cannabis and
placebo on PTSD symptom severity measured by CAPS-5 total severity scores during Stage 1.
Phase:
Phase 2
Details
Lead Sponsor:
Multidisciplinary Association for Psychedelic Studies